“The toxicology data package of etranacogene dezaparvovec and AMT-060 included single IV dose toxicity studies up to duration of 6 months with 6 months observation period in C57Bl/6 mice and cynomolgus macaques, and a reproduction and developmental toxicity study in mice.”
Mouse (C57Bl/6) and cynomolgus monkey; single IV dose studies up to 6 months
“The toxicology data package of etranacogene dezaparvovec and AMT-060 included single IV dose toxicity studies up to duration of 6 months with 6 months observation period in C57Bl/6 mice and cynomolgus macaques, and a reproduction and developmental toxicity study in mice.”
Male mouse only (paternal germline transmission/fertility study with predecessor vector)
“The risk of germline transmission of the HEMGENIX predecessor was evaluated in healthy male mice administered 2.3x1014 gc/kg and mated with healthy naïve female mice on Day 6 post-dose.”
✓ VerifiedFDA summary basis for approval, p. 11Source ↗
Species: carcinogenicity
Not conducted
“Dedicated studies on carcinogenicity were not conducted with AMT-061 (nor AMT-060).”
Yes: predecessor vector AMT-060 (differs by two base pairs/one amino acid) used in several toxicology studies
“AMT-060 instead of etranacogene dezaparvovec was used in several toxicological studies provided. This is regarded acceptable as AMT-060 differs only in two base pairs/one amino-acid to the final GTMP AMT-061”